These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 19650211)
1. Words of wisdom. Re: Tumor size does not predict risk of metastatic disease or prognosis of small renal cell carcinomas. Remzi M Eur Urol; 2009 Mar; 55(3):751-2. PubMed ID: 19650211 [No Abstract] [Full Text] [Related]
2. Tumor size does not predict risk of metastatic disease or prognosis of small renal cell carcinomas. Klatte T; Patard JJ; de Martino M; Bensalah K; Verhoest G; de la Taille A; Abbou CC; Allhoff EP; Carrieri G; Riggs SB; Kabbinavar FF; Belldegrun AS; Pantuck AJ J Urol; 2008 May; 179(5):1719-26. PubMed ID: 18343437 [TBL] [Abstract][Full Text] [Related]
3. Tumor size predicts synchronous metastatic renal cell carcinoma: implications for surveillance of small renal masses. Kunkle DA; Crispen PL; Li T; Uzzo RG J Urol; 2007 May; 177(5):1692-6; discussion 1697. PubMed ID: 17437785 [TBL] [Abstract][Full Text] [Related]
4. Words of wisdom. Re: efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. Bedke J; Pelzer AE Eur Urol; 2008 Nov; 54(5):1200-1. PubMed ID: 19051381 [No Abstract] [Full Text] [Related]
5. Words of wisdom: re: prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Karam JA; Wood CG Eur Urol; 2013 Apr; 63(4):769. PubMed ID: 23438394 [No Abstract] [Full Text] [Related]
6. The metastatic potential of renal tumors: Influence of histologic subtypes on definition of small renal masses, risk stratification, and future active surveillance protocols. Daugherty M; Sedaghatpour D; Shapiro O; Vourganti S; Kutikov A; Bratslavsky G Urol Oncol; 2017 Apr; 35(4):153.e15-153.e20. PubMed ID: 28202224 [TBL] [Abstract][Full Text] [Related]
7. Words of wisdom. Re: Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Stillebroer AB, Mulders PFA, Boerman DC, Oyen WJG, Oosterwijk. E Eur Urol. In press. DOI: 10.1016/j.eururo.2010.03.015. Sciarra A Eur Urol; 2010 Aug; 58(2):316. PubMed ID: 20845535 [TBL] [Abstract][Full Text] [Related]
8. Words of wisdom: Re: Pazopanib versus sunitinib in metastatic renal-cell carcinoma. Ouzaid I; Rini B Eur Urol; 2014 Mar; 65(3):667-8. PubMed ID: 24484761 [No Abstract] [Full Text] [Related]
9. Words of wisdom: Re: Pazopanib versus sunitinib in metastatic renal-cell carcinoma. Sun M; Trinh QD; Perrotte P; Karakiewicz PI Eur Urol; 2014 May; 65(5):1014-5. PubMed ID: 24646500 [No Abstract] [Full Text] [Related]
10. Words of wisdom: Re: Objective measures of renal mass anatomic complexity predict rates of major complications following partial nephrectomy. Pignot G; Bessede T; Patard JJ Eur Urol; 2013 May; 63(5):963. PubMed ID: 23541256 [No Abstract] [Full Text] [Related]
11. Words of wisdom. Re: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Escudier B, Pluzanska A, Koralewski P, et al., for the AVOREN Trial investigators. Shariat SF; Bolenz C; Karakiewicz PI Eur Urol; 2008 Oct; 54(4):948-9. PubMed ID: 18953756 [No Abstract] [Full Text] [Related]
12. Role of the argyrophilic nucleolar organizer regions in tumor detection and prognosis. Pich A; Chiusa L; Margaria E Cancer Detect Prev; 1995; 19(3):282-91. PubMed ID: 7750118 [TBL] [Abstract][Full Text] [Related]
13. Words of wisdom. Re: Prognostic risk stratification and clinical outcomes in patients undergoing surgical treatment for renal cell carcinoma with vascular tumor thrombus . Bastian PJ Eur Urol; 2008 Feb; 53(2):450-1. PubMed ID: 18329978 [No Abstract] [Full Text] [Related]
14. Predictors of locally advanced and metastatic disease in patients with small renal masses. Kates M; Korets R; Sadeghi N; Pierorazio PM; McKiernan JM BJU Int; 2012 May; 109(10):1463-7. PubMed ID: 21933329 [TBL] [Abstract][Full Text] [Related]
15. Words of wisdom. Re: Prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation: analysis of trends over time. Catalona WJ Eur Urol; 2013 Jan; 63(1):179. PubMed ID: 23218491 [No Abstract] [Full Text] [Related]
16. Words of wisdom. Re: Ureteroscopic treatment of patients with small, painful, non-obstructing renal stones: the small stone syndrome. Dretler SP; Eisner BH Eur Urol; 2013 Jan; 63(1):182. PubMed ID: 23218495 [No Abstract] [Full Text] [Related]
17. Words of wisdom. Re: Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. Re: Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. Albers P Eur Urol; 2011 Nov; 60(5):1124-5. PubMed ID: 21961745 [No Abstract] [Full Text] [Related]
18. Primary tumor size in renal cell cancer in relation to the occurrence of synchronous metastatic disease. Zastrow S; Phuong A; von Bar I; Novotny V; Hakenberg OW; Wirth MP Urol Int; 2014; 92(4):462-7. PubMed ID: 24642839 [TBL] [Abstract][Full Text] [Related]
19. Words of wisdom. Re: High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. Gasser T Eur Urol; 2007 Dec; 52(6):1795-6. PubMed ID: 18074440 [No Abstract] [Full Text] [Related]
20. Words of wisdom. Re: final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. Logothetis CJ; Siefker-Radtke A Eur Urol; 2010 Apr; 57(4):728-9. PubMed ID: 20965043 [No Abstract] [Full Text] [Related] [Next] [New Search]